Numbers

The Numbers: Reckitt Benckiser Group (RKT.L)

Reckitt trades at 7.4x adj EV/EBITDA — roughly half the consumer staples sector average of 13–16x — despite generating over £2bn of free cash flow every year and sustaining adjusted operating margins above 20% for five consecutive years. The market is not pricing the Hygiene/Health franchise; it is pricing the IFCN (infant nutrition) liability, open-ended NEC litigation exposure, and a topline that has gone nowhere in five years. The single variable most likely to re-rate or de-rate this stock is IFCN strategic resolution: a clean divestiture at fair value removes the primary discount; further impairments or adverse litigation rulings validate it.

Snapshot

All financials in GBP millions unless stated. Share price in pence (p) as traded on the London Stock Exchange.

Revenue & Earnings Power

The topline has been range-bound at £13–15bn for five years: post-COVID hygiene normalisation offset IFCN volume declines, keeping revenue flat in aggregate. Adjusted EBITDA has held at £3.1–3.8bn — the FY2024 step-down to £3.1bn (23.3% margin vs 26%+ in prior years) is IFCN mix drag, not Hygiene/Health deterioration.

Gross margins are remarkably stable at 58–60%, confirming pricing power in the branded portfolio. Adjusted EBITDA margin compression in FY2024 is structural IFCN mix drag: Nutrition was a higher-margin segment and its volume decline (-9.8% LFL) reduces fixed-cost leverage group-wide.

Q4 FY2024: The Impairment Quarter

Three quarters of FY2024 showed stable adj EBITDA of £750–820M. Q4 absorbed a £3.8bn non-cash goodwill write-down on the IFCN business, producing a -£1,981M GAAP operating income figure that collapses the full-year reported numbers. The underlying machine did not deteriorate.

Q4 GAAP operating income of -£1,981M is entirely non-cash. The adj EBITDA series (green) shows no deterioration — Q4 matched Q3. Readers watching GAAP EPS should use adjusted metrics to assess the underlying business.

Cash Generation — Are the Earnings Real?

Operating cash flow tracked adjusted net income at roughly 107% across 2020–2024 — earnings are fully backed by cash. The red bars (reported NI) collapsing in 2023–2024 are entirely non-cash impairments; FCF was unaffected. Capex runs at 3.5–3.6% of revenue, confirming a low physical-capital-intensity model. FCF / adj net income averaged ~85% over five years.

Capital Allocation

Reckitt has returned over £1.5bn annually to shareholders through dividends and buybacks every year since 2020. The progressive dividend of 174.6p per share is covered 1.7x by FCF, providing meaningful buffer in a revenue-contraction year. Buybacks were cut sharply to £200M in 2021 (balance-sheet discipline post-MJN leverage) then rebuilt toward £500M — a sign of growing management confidence in FCF durability.

Balance Sheet Health

Net debt has held in a £5.2–5.9bn range. The FY2024 uptick to 1.9x net debt / adj EBITDA reflects the EBITDA step-down rather than new borrowing. Management targets 1.5–2.0x, so current leverage is at the top of its own comfort zone.

Valuation vs Five-Year History

Current EV/EBITDA of 7.4x is 35% below the five-year mean of 11.3x and at least 40% below the closest consumer staples peers. On a forward adj P/E of 8.2x against FY2025 adj EPS of £3.42 (beat at FY2025 results), the stock is pricing in ongoing operational deterioration that has not yet appeared in cash flow.

Share Price: A Six-Year Drawdown

From a peak of ~7,280p in August 2020 to 2,406p today: a 67% decline. The stock appears to have found a floor around 2,280–2,440p since late 2024, consistent with the market pricing in most of the IFCN write-down and partial NEC litigation reserve. A sustained move below 2,200p would suggest further impairment expectations are being layered in.

Peer Comparison

Peer EV/EBITDA figures are approximate consensus estimates. US peer revenue and NI margin sourced from latest annual filings in native USD. ULVR.L and HLN.L excluded (insufficient data available).

Reckitt's 7.4x EV/EBITDA vs P&G at ~19x and Colgate at ~21x is a 60% discount to US consumer staples benchmarks. Adjusted NI margin of 17.6% is above US peers, which makes the valuation gap harder to justify on fundamentals alone. The entire discount is a IFCN/litigation risk premium — which cuts both ways.

Fair Value Scenarios

Using EV/EBITDA reversion as the primary method, anchored on FY2024 adj EBITDA of £3,105M and net debt of £5.9bn:

Bear (5.5x EBITDA): IFCN volumes deteriorate further, NEC litigation reserve of £1–2bn crystallises. EV = £17.1bn → equity £11.2bn / 711.5M shares = ~1,570p. Downside ~35%.

Base (9.0x EBITDA): IFCN disposed at book, litigation settled at manageable level, Hygiene/Health re-rated modestly. EV = £27.9bn → equity £22.0bn / 711.5M shares = ~3,090p. Upside ~28%.

Bull (12.0x EBITDA): Full sector re-rating post IFCN exit, adj EBITDA recovers to £3.5bn on volume growth. EV = £42.0bn → equity ~£36bn / 711.5M shares = ~5,060p. Upside ~110%.

The analyst consensus target of 2,950p aligns with the base scenario. The asymmetry is significant: the bear case requires additional impairments beyond the £6.3bn already taken, while the bull case simply requires IFCN clarity and the Hygiene/Health multiple to mean-revert.

The numbers confirm that Reckitt's core Hygiene/Health franchise is intact: £2bn+ of free cash flow, 58–60% gross margins, and 20%+ adjusted operating margins held consistently through five years of portfolio disruption. What they contradict is the "broken business" narrative — the cash generation is not broken, the adjusted earnings are not broken; only the GAAP P&L is broken because of £6.3bn of non-cash goodwill write-downs. What to watch next: an IFCN strategic decision (divestiture announcement or formal exit timeline), NEC litigation reserve size at the next results, and whether adj EBITDA recovers toward £3.3–3.5bn in FY2025 as Hygiene/Health volumes grow. Those three data points will determine whether 2,406p is a floor for a quality franchise at deep value, or a fair price for a structurally challenged business awaiting further write-downs.